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ABSTRACT 
Refractory anemia with ring sideroblasts (RARS) is characterized by anemia, erythroid 
apoptosis, and mitochondrial ferritin (FTMT) accumulation. Granulocyte-colony-stimulating 
factor (G-CSF) inhibits some of these features in vitro and in vivo and can in combination 
with erythropoietin normalize hemoglobin levels. The focus for this thesis was to investigate 
ABCB7 gene expression levels and mutational status in CD34+ cells and erythroblasts from 
MDS patients in order to understand mechanisms underlying the pathogenesis of RARS as 
well as the anti-apoptotic effects of G-CSF. Furthermore, we wanted to test the hypothesis 
that ABCB7 is a key mediator of aberrant iron accumulation in acquired RARS.  
To dissect these mechanisms, the CD34+ compartment of RARS bone marrow, as well as 
erythroblasts derived from CD34+ cells in an erythroblast culture system were subjected to 
gene expression analysis (GEP). Erythroblasts were also analyzed after incubation with G-
CSF. The mutational and DNA methylation status of ABCB7 and other key down-regulated 
genes was assessed. To study the ABCB7 role in aberrant iron accumulation in RARS 
erythroblasts, we modulated the expression of ABCB7 in several cellular systems.  
ABCB7 is not mutated in RARS. However, CD34+ ABCB7 expression level was 
significantly lower compared to other MDS subtypes. Furthermore, there was a significant 
inverse relation between ABCB7 expression and the percentage of ring sideroblasts. In 
contrast to normal bone marrow, ABCB7 expression decreased during erythroid 
differentiation of RARS CD34+ cells. Other down-regulated key genes included MFN2, 
STAT5B, FANCC and the negative apoptosis regulator MAP3K7. Neither ABCB7, nor other 
down-regulated key genes in RARS showed hypermethylation. Several genes involved in 
erythropoiesis were significantly over-expressed in RARS CD34+ cells but showed normal 
or decreased expression in differentiating erythroblasts. Deregulated pathways in RARS 
erythroblasts included apoptosis and mitochondrial function.  
Interestingly, the mitochondrial pathway including MFN2 was significantly modified by G-
CSF, and several heat shock protein genes were up-regulated, as evidence of anti-apoptotic 
protection of erythropoiesis. However, G-CSF had no effect on the expression of iron-
transport or erythropoiesis-associated genes.  
ABCB7 down-regulation led to marked up-regulation of FTMT in K562 cells, while 
inhibiting growth and erythroid differentiation. In normal bone marrow, ABCB7 silencing 
reduced erythroid colony growth, and induced erythroid apoptosis and a gene expression 
pattern similar to that observed in RARS day 7 erythroblasts. Importantly, down-regulation 
led to the accumulation of mitochondrial iron, in the form of FTMT. ABCB7 up-regulation 
potentiated erythroid differentiation in K562 cells, and restored erythroid colony growth and 
decreased FTMT expression level in RARS CD34+ BM cells. Mutations in the SF3B1gene, 
a core component of the RNA splicing machinery, were recently identified in a high 
proportion of patients with RARS. Of the nine RARS patients included in our study, 7 
carried SF3B1 mutations. Interestingly, SF3B1 silencing resulted in down-regulation of 
ABCB7.  
Our findings support an essential role of ABCB7 in the phenotype of acquired RARS and 
suggest a relation between SF3B1 mutations and ABCB7 down-regulation that warrants 
further investigation.  
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